a b s t r a c t NRH:quinone oxidoreductase 2 enzyme (NQO2) is a potential therapeutic target in cancer and neurodegenerative diseases, with roles in either chemoprevention or chemotherapy. Here we report the design, synthesis and evaluation of non-symmetrical furan-amidines and their analogues as novel selective NQO2 inhibitors with reduced adverse off-target effects, such as binding to DNA. A pathway for the synthesis of the non-symmetrical furan-amidines was established from the corresponding 1,4-diketones. The synthesized non-symmetrical furan-amidines and their analogues showed potent NQO2 inhibition activity with nano-molar IC 50 values. The most active compounds were nonsymmetrical furan-amidines with meta-and para-nitro substitution on the aromatic ring, with IC 50 values of 15 nM. In contrast to the symmetric furan-amidines, which showed potent intercalation in the minor grooves of DNA, the synthesized non-symmetrical furan-amidines showed no affinity towards DNA, as demonstrated by DNA melting temperature experiments. In addition, Plasmodium parasites, which possess their own quinone oxidoreductase PfNDH2, were inhibited by the non-symmetrical furanamidines, the most active possessing a para-fluoro substituent (IC 50 9.6 nM). The high NQO2 inhibition activity and nanomolar antimalarial effect of some of these analogues suggest the lead compounds are worthy of further development and optimization as potential drugs for novel anti-cancer and antimalarial strategies.
widely distributed in human heart, brain, lung, liver and skeletal muscles [2] . The NQO2 enzyme catalyses the reduction of quinones and quininoid compounds into hydroquinones [3] . The reduction process proceeds via a ping-pong mechanism in which two electrons are transferred from the cosubstrate to FAD molecule and subsequently to the substrate [4] . The co-substrate used by NQO2 includes N 1 -ribosyl dihydronicotinamide (NRH) and its N 1 -methyl, N 1 -(n-propyl), and N 1 -benzyl analogues [5] , with a high affinity for the synthetic N 1 -benzylnicotinamide [6] .
NQO2 is a potential therapeutic target in cancer as it is highly expressed in tumour cells [5] and has an indirect role in the activation of NF-k B through interference with the TNF-signalling pathway [7, 8] . The activation of NF-k B results in the suppression of cell apoptosis [9] and the protection of the tumour cells against chemotherapeutic drugs and ionizing radiation [10] . In addition, the knock-down of NQO2 in prostate cancer results in lowering the proliferation rate of the cells [11] . As a consequence, NQO2 inhibition has a potential chemotherapeutic and/or chemopreventive activity. In addition, the role of NQO2 in the reduction of menadione (2-methyl-1,4-naphthaquinone, Vitamin K) [12] was linked to hepatic toxicity [13] .
In our laboratory, virtual screening of the National Cancer Institute (NCI) chemical database with the X-ray crystallized NQO2 structure (PDB code 1QR2, resolution 2.1 Å) and inhibition studies led to the identification of furan-amidines as novel inhibitors of NQO2 (Table 1 ) [14] . In our search for more potent selective NQO2 inhibitors, we focused on the design, synthesis and evaluation of non-symmetrical furan, pyrrole and N-methylpyrrole-amidines, furan-imidate, furan and thiophene-amide and reversed amidines. Symmetric furan-amidines (e.g. compounds 2 and 3) have previously been studied with regard to their DNA intercalation activity [15] . These compounds, with two positively charged amidine groups at pH 7.4, accumulate inside the nucleus and bind in the DNA minor groove. In contrast, non-symmetrical furan-amidine 1 distributes in cytoplasm, possibly into mitochondria, without any nuclear accumulation [15] . To enhance the selectivity of the targeted compounds for NQO2, we focused on the non-symmetrical compounds bearing one amidine group.
Symmetric furan-amidine, like 2 and its prodrug DB289 [16] , are also known to potently inhibit Plasmodium growth, causative agents of malaria, where they are localized in the nuclei and bind the genome affecting DNA functions [17] . For this mode of action they also showed serious hepato and nephro-toxicity [18] . NQO2 has been suggested to be one of the targets for the antimalarial quinolines that were shown to specifically bind and inhibit NQO2 [19] . In addition, Plasmodium parasites possess also their own quinone oxidoreductase, that is called PfNDH2, a type II NADH:-quinone oxidoreductase, an atypical complex I, not directly involved in the transmembrane proton pumping [20] . PfNDH2 is inhibited by heterocyclic quinolones similarly to NQO2 [21, 22] . Despite PfNDH2 and NQO2 shows high divergence as they evolved independently into enzymes with similar functions [23] , the possibility that their cofactor pockets have similarities in their binding properties could be hypothesized. Therefore, here we also evaluated the antimalarial activity of the non-symmetrical furan-amidine analogues.
Results and discussion

Synthesis
The symmetric furan-amidine 2, and a range of nonsymmetrical furan-amidine 1, pyrrole-and N-methypyrrole-amidines were synthesized using a multi-step pathway starting with the preparation of the 1,4-diketone compounds 6a-l. The 1,4-diketone compounds 6a-l were prepared using a modified method described by Nevar and coworkers [24] involving a condensation reaction between a methyl aryl ketone 4a-l and abromomethyl aryl ketone 5a or 5b (Scheme 1). The 1,4-diketone compounds 6a-l were synthesized in low to good yield (9e61%) depending on the substituent on the phenyl ring, with the better yields (>45%) obtained when the methyl aryl ketone starting material had an electron-withdrawing group on the phenyl ring e.g. 4f, 4k and 4l.
The 1,4-diketones 6a and 6b were also synthesized using a Stetter reaction starting from Mannich bases and 4-formylbenzonitrile. The long duration of the Stetter reaction (heating under reflux for 24e72h), the difficult purification of the 1,4-diketones from the heterogeneous reaction mixture and the poor yields (6a (36%), 6b (20%)) limited the use of the Stetter reaction for the synthesis of the 1,4-diketone compounds.
The 1,4-diketones 6a-l were the intermediates for the preparation of the final amidine compounds (Scheme 2). All compounds 6a-l possess a nitrile group that is the precursor for the amidine group. Using the method described by Pinner, the nitrile groups 6a-l were converted into the amidines 1,2 and 8a-l via the formation of the ethyl imidate (iminoether) intermediates 7a-l [25] . Ethyl imidate intermediates 7a-l were prepared by reacting the 1,4-diketone compounds 6a-l with ethanol in the presence of dry hydrogen chloride gas [26] . In this step the 1,4-diketones intermediates 6a-l were cyclized into furan ring and the nitrile groups were converted into ethyl imidates 7a-l. According to the literature the best ratio of ethanol and acetyl chloride to be used for the formation of imidate intermediate is 1 (nitrile): 8 (acetyl chloride): 12 (ethanol) [26] . However, the use of this ratio of starting materials with the 1,4-diketone 6a resulted in the formation of the furan ring without the conversion of the nitrile group into imidate (data are not shown). Therefore, the equivalents of acetyl chloride and ethanol were doubled or tripled to achieve cyclization and conversion of nitrile into imidate intermediate in the same step. The ethyl imidates 7a-l were obtained as hydrochloride salts in very good yields (>50% except for 7b and 7j). The furan-amidines 1, 2 and 8c-l were prepared through the reaction of ethyl imidate intermediates 7a-l with ammonium acetate in absolute ethanol [27] . The final products 1, 2 and 8c-l were obtained as acetate salts in good yields (>60%).
Pyrrole analogues of the non-symmetrical furan-amidine 1 were proposed as a potential way to improve the water solubility of compound 1. The non-symmetrical pyrrole-and N-methyl pyrroleamidines 13 and 14, were synthesized starting from the 1,4-diketone intermediate 6a. Firstly, the 1,4-diketone 6a was cyclized into pyrrole-9 and N-methylpyrrole 10 using ammonium acetate in ethanol and N-methylamine, respectively [28] . Next, the ethyl imidate intermediates 11 and 12 were prepared through the reaction of the nitrile groups in 9 and 10 with ethanol in the presence of dry hydrogen chloride gas [26] . Finally, the amidines 13 and 14 were obtained after the treatment of the ethyl imidate intermediates 11 and 12 with ammonium acetate in ethanol (Scheme 3) [27] .
Molecular modelling
Computational molecular docking was performed for the compounds synthesized (non-symmetrical furan-amidines 1 and 8c-l, pyrrole-13 and N-methylpyrrole-amidines 14) into the X-ray crystal structure of human NQO2 with bound FAD (PDB code 1QR2; resolution 2.10 Å) [29] . The parent compound 1 of the nonsymmetrical furan-amidine series docked with good shape complementarity into the NQO2 pocket, with hydrogen bonding between the amidine functionality and Gln122, along with pÀp stacking of the ligand aromatic moieties against the isoalloxazine ring of the FAD (Fig. 1A) . This was supplemented by pÀp stacking with Phe178 0 and Phe126 0 and further nonpolar interactions with Trp105, Met154 0 and Cys121'. Indeed pÀp stacking was also a common feature of the docked poses of compounds 8c-l, 13 and 14. The docked pose of 1 was 40.9 kJ/mol similar to the remaining compounds 8c-l, 13 and 14, which had an average docked score of 40.0 kJ/mol and range 5.4 kJ/mol (Table S1 ). Whilst stacking was a Table 1 Non-symmetrical (1) and symmetric (2) and (3) furan-amidine lead compounds [14] .
common predicted feature of the synthesized compounds, the orientation of the amidine group appeared to vary, adopting three different poses: interaction (1) with Gln122, (2) with Asn161 0 or (3) with Thr71 (Table S2 ). The poses 1e3 are illustrated by compounds 8k (Fig. 1B) , 8h ( Figure 1C ) and 14 ( Fig. 1D) , respectively. For compounds 8e, 8f and 8g, interaction with Asn161 was coupled with interaction with the backbone O atom of Gly174. These three compounds were able to adopt an alternative pose, with Gln122; however, in all three cases the Asn161'/Gly174 pose scored higher by 2e5 kJ/mol. Interestingly the bulkier compounds (8i, 8j, 14) were able to form interactions with Thr71. Despite the clearly subtle balance between polar and nonpolar contacts in the NQO2 active site, all compounds exhibited a reasonably complementary binding pose. The exception to the three poses was compound 8c, with the 3-amidino group, which adopted an alternative pose with only partial stacking, the main feature being a charge pair with the side chain of Glu193. That did not contact any polar residues. Indeed, the highest scores were predicted for 8h and 8f and the lowest for 8c.
Inhibition of recombinant human NQO2 enzyme activity
The ability of the synthesized compounds 1, 2, 8c-l, 13 and 14 to inhibit the NQO2 enzyme was determined by a spectrophotometric method that monitored the discolouration of the blue redox dye 2,6-dichlorophenolindophenol (DCPIP) at pH 7.4. The rate of discolouration of DCPIP is correlated with the rate of NQO2 activity. The IC 50 values for resveratrol (positive control), the symmetric furan amidine 2 and the non-symmetrical furan-, pyrrole-and Nmethylpyrrole-amidines 1, 8c-l, 13 and 14, respectively, are shown in Table 2 . For the compounds with IC 50 less than 1.0 mM the inhibitory potency was also evaluated in the presence of bovine serum albumin (BSA).
The positive control resveratrol showed an IC 50 value of 913.0 ± 2.3 nM. All of the synthesized non-symmetrical furan-, pyrrole-and N-methylpyrrole amidines with a para-amidine showed excellent inhibitory activity, with IC 50 values in the nanomolar range (15.0e510.0 nM). The most potent inhibitors were the non-symmetrical furan-amidine inhibitors with meta-and para-NO 2 group 8k and 8l, respectively; both showed IC 50 values of 15 nM, followed by para-Br group 8f with an IC 50 of 27 nM. Although docked scores did not provide strong correlation with measured IC 50 values for the overall compound set, 8f and 8k did feature among the highest scoring ligands (Table S1 ). From the docked poses, whereas the amidine groups of 8f and 8l preferred interaction with Asn161 0 , the amidine of 8k interacted with Gln122 ( Fig. 1B) (Table S2 ). For 8l, the nitro group makes a polar interaction with the hydroxyl of Thr71, with ligand NO … O Thr71 distance of 2.8 Å; for 8k, the nitro group approaches Asn161' (closest heavy atom separation of 3.6 Å) without specific interaction (Fig. 1B) . It was found that the position of the amidine group on the phenyl group is essential for NQO2 inhibition activity as the movement of amidine group from para-position 1 into meta-position 8c led to the total loss of activity. This is somewhat in accord with the predicted low score of 8c, which did not seem able to make optimal aromatic stacking interactions due to its active site fit. As a result, the compounds that bear the amidine group at the paraposition were subsequently synthesized to increase the likelihood of NQO2 inhibitory activity. In addition, the symmetric furanamidine 2 was tested for NQO2 activity and it had a very good IC 50 of 35 nM, which is more potent than that we reported previously [14] . The likely reason for this is that compound 2 (NSC305831) in the study by Nolan et al. [14] was sourced directly from NCI and was evaluated without full purity checks. Compound 2 was further used as a positive control in the DNA melting profile experiments.
The effect of length and branching of the alkyl groups on NQO2 inhibitory ability was also studied by preparing non-symmetrical furan-amidines with homologous alkyl substituents 8h,i,j,k. Both non-symmetrical furan-amidines 1 (R ¼ H) and 8h (R ¼ Me) showed approximately similar IC 50 values of~70 nM. An increase in the alkyl chain length to ethyl 8i and t-butyl 8j led to the increase of the IC 50 values by 3 and 8 fold, respectively, when compared with 1. This can be explained by the increase in the steric hindrance of the synthesized compounds with growing the alkyl chain length, reflected by a progressively larger ChemScore steric clash value, of 5.1, 6.2 and 6.8 kJ/mol for 8h, 8i and 8j respectively.
The ability of the active compounds (IC 50 less than 1.0 mM), to inhibit NQO2 in the presence of bovine serum albumin (BSA) was studied, as serum albumin is the major macromolecule in blood and protein binding can decrease activity [30] . The tested compounds showed a slight increase (2e7 fold) in IC 50 values compared to the values obtained in the absence of BSA. The low affinity of these potential NQO2 inhibitors for serum albumin provides a good evidence for the ability of these compounds to be distributed into tumour cells without an excessive binding to serum proteins.
Furan-amidines 8 were screened at 10 mM to determine whether they inhibit NQO1. None of the furan-amidines showed inhibition of NQO1 enzyme activity, demonstrating that they are selective NQO2 inhibitors.
Cell toxicity
All the synthesized compounds were evaluated in vitro against four breast cancer cell lines, MDA-MB 468, MDA-MB 231, MCF-7 and T47D (Table 3) . These cell lines were chosen because they showed varying cellular activity of NQO2 [31] and thereby could reveal whether toxicity is in any way related to NQO2 expression. Toxicity was determined following 96 h exposure to each of the synthesized compounds and compared to that observed for resveratrol. Remarkably, for each compound there was little difference in toxicity between the different cell lines. Resveratrol was the least toxic compound with an IC 50 of~60 mM in all four cell lines. Interestingly all the non-symmetrical compounds (with the exception of 8c) showed greater toxicity towards all of the cell lines than the symmetric amidine from which they were derived (IC 50 values of 2.0e4.0 mM compared to 12.5e14.0 mM).
DNA melting temperature profiles (T m )
To avoid possible DNA off-target effects, it was crucial to ensure that new NQO2 have minimal or negligible binding affinity towards double-stranded DNA. The elevation in the DNA melting temperature (T m ) as a result of ligand intercalation or minor grove binding can be used as an indicator for the interaction between drugs and DNA [32] . To assess the binding affinity of synthesized compounds towards DNA, the T m values of calf thymus double-stranded DNA in the absence and presence of the synthesized non-symmetrical furans-amidines 1 and 8d-h and N-methylpyrrole-amidine 14 were measured (Table 4) . Two positive controls were used, doxorubicin and the symmetric furan-amidine 9, known intercalaters that have Table 2 The IC 50 values for the inhibition of NQO2 by the targeted compounds (values are given ± SE).
a No inhibitory activity when tested at 10 mM. 2.4 ± 0.8 2.0 ± 0.6 2.6 ± 0.9 2.8 ± 0.3 8e 3.8 ± 0.9 3.2 ± 0.2 3.7 ± 0.9 3.6 ± 0.6 8f 2.5 ± 0.7 2.7 ± 0.6 2.
3.4 ± 0.9 3.1 ± 0.6 3.2 ± 0.9 3.8 ± 0.9 13 3.6 ± 0.7 3.8 ± 0.9 3.2 ± 0.6 3.4 ± 1.1
No measurable toxicity at the maximum concentration tested (10 mM).
the ability to form complexes with DNA via minor groove binding at AT sequences leading to elevation in DNA T m values [33] . As expected, the DNA melting temperature values (T m ) increased by approximately 20 C in the presence of the positive controls (doxorubicin and the symmetric furan-amidine 2). In contrast, all of the non-symmetrical furan-amidines 1 and 8d-h only led to a slight increase in DNA T m values of approximately 2.0e4.4 C, thus indicating minimal or negligible interactions of these ligands with DNA. The non-symmetrical N-methylpyrroleamidine 14 showed the lowest binding affinity for DNA with an increase of only 0.9 C in DNA melting temperature. The large difference seen for symmetric and non-symmetrical furan-amidines in their effect on DNA melting can be explained by the difference in their ability and affinity to bind to DNA. It was previously reported that the amidine groups of symmetric furan-amidines (e.g. 2) form strong H-bonds with the thymine keto-groups forming the floor of DNA minor grooves, and the furan ring fits well between the walls of the groove, which consists of deoxyribose groups [34] . Compounds 1, 8d-h with one amidine group have less ability to form Hbonds with DNA compared to compound 2, and as consequence show less affinity to bind DNA. T m profiles (see Fig. 2 ) recorded as a temperature dependence of UV absorbance at 260 nm demonstrate this large difference in binding affinities of the studied ligands (i.e. doxorubicin, the symmetric furan-amidine 2 and the nonsymmetrical furan-amidine 8d on DNA melting temperatures) in a most pictorial way.
The symmetric furan-amidine 2 with two positively charged amidine groups showed an increase in the DNA melting temperature, which is correlated with literature data [15] . All nonsymmetrical furan-and N-methylpyrrole-amidine compounds did not increase the DNA T m , which means that these compounds with one positively charged amidine group has low binding affinity to DNA compared with compounds with two positively charged amidine groups.
Antimalarial activity
We evaluated if non-symmetrical furan-amidines showed activity against parasite growth. Compounds 8e, 8g and 8h showed nanomolar IC 50 values, 10e140 nM (Table 5) , performing even better than the observed toxicity in mammalian cells. No nuclear localization was observed suggesting an alternative mode of action when compared with 2 (data not shown). At this stage we do not know the target for these molecules in Plasmodium parasites, nevertheless, non-symmetrical furan-amidines are promising as new antimalarial drug-leads.
Conclusion
Efficient syntheses of the lead non-symmetrical furan-amidine 1 and a series of non-symmetrical furan-, pyrrole-and N-methylpyrrole-amidines have been carried out using multi-step synthetic pathways. The synthesis of the target compounds started from the preparation of substituted 1,4-diketone intermediates, which were cyclized to different 5-membered heterocycles using a variety of reagent. The nitrile group served as the precursor for the amidine group. The substitution of the phenyl ring in the case of furanamidines, specifically with a nitro-group 8k and 8l resulted in the most active NQO2 inhibitors. The isosteric replacement of the furan ring into the more water-soluble 5-membered heterocycles, pyrrole 13 and N-methylpyrrole 14 led to a decrease in the NQO2 inhibitory activities, when compared with the lead non-symmetrical furanamidine 1. The non-symmetrical furan-amidines showed very low binding affinities towards DNA when compared to the symmetric furan-amidines, which are known as DNA intercalators. However, very surprisingly these non-symmetrical compounds showed greater toxicity than their symmetric analogues. There was no difference in toxicity towards the four different cell lines, which suggests that toxicity is independent of NQO2. Identification of the mechanism of the toxicity of these agents forms the basis of future work. Nevertheless, we have clearly identified potent and selective NQO2 inhibitors bearing the non-symmetrical furan-amidine scaffold which warrant further investigation as potential drugs in chemotherapy and chemoprevention. Their activity against the Plasmodium parasite was very high and suggests that the furan amidines could be used as lead compounds as novel antimalarials.
Experimental
Synthesis
Chemicals were purchased from Sigma-Aldrich, solvents were purchased from Fisher Scientific, and deuterated solvents were purchased from Goss. Melting points were measured using a Stuart Scientific melting point apparatus SAMP10. Infrared spectra were recorded in the solid state using a JASCO fourier transform infrared spectrophotometer. Bruker Avance 300 and 400 MHz spectrometers were used to record 1 H and 13 C NMR spectra. Chemical shifts are quoted in parts per million (ppm) and referenced to tetramethylsilane (d ¼ 0). Mass spectrometry was carried out in the School of Chemistry, University of Manchester using a Micromass Platform II instrument. Molecular ion peaks are reported as mass/charge (m/ z) ratios. Solvents were evaporated on a Buchi rotavapor R-200 equipped with a Buchi heating bath B-490. Thin layer chromatography (TLC) was performed using silica gel 60 on aluminium sheets with F254. The spots were visualized using a UV Mineralight lamp (254/365) UVGL-58. Column chromatography was performed using silica gel particle size 40e63 mm. A BECKMAN DU 7400 spectrophotometer was used to determine enzyme activity. A Grant JB series water bath was used to heat the buffer to 37 C.
3.1.1. General procedure for the synthesis of 1,4-diketone intermediates 6a-l Zinc chloride (2.0 equivalents) was added to dry toluene or dry THF, absolute ethanol (1.5 equivalents) and triethylamine (1.5 equivalents). The mixture was stirred at room temperature for 1e2 h. Methyl aryl ketone (1.5 equivalents) and a-bromomethyl aryl ketone (1.0 equivalent) were added and the mixture was stirred at room temperature for 3e7 days and monitored by TLC (20% ethyl acetate in hexane). Unless otherwise stated, the workup involved: the reaction mixture was quenched by the addition of 10% (v/v) cold aqueous sulfuric acid solution (10 mL) and extracted with ethyl acetate (20 mL). The organic layer was washed with brine, dried over dry MgSO 4 and concentrated. 3.1.1.2. 1,4-Bis-(4-cyanophenyl)-1,4-butadione 6b. Toluene was decanted and the pale yellow residue gum was dissolved in DMF (~80 C, 50 mL). Compound 6b was crystallized from DMF as a pale yellow solid by the addition of methanol (10 mL), filtered under vacuum and washed with cold methanol to yield 0.81 g (61.0%): mp 247e249 C (Lit. mp 260e265 C) [35] ; the spectroscopic data (IR, 1 H and 13 C NMR) were identical to those reported in the literature [35] . þ , requires 300.0995, error 0.5 ppm.
1-(4-Cyanophenyl)-4-(4-ethylphenyl)-1,4-butadione
6i. The crude reaction mixture was purified by column chromatography using EtOAc-hexane (1:9) as the mobile phase to give 0.14 g (18%) as a colourless solid: mp 126e128 C; IR (cm À1 
Synthesis of 4-(5-phenyl-1H-pyrrol-2-yl)benzonitrile 9
Ammonium acetate (0.31 g, 4.0 mmol) was added to a stirred solution of 6a (0.20 g, 0.8 mmol) in absolute ethanol (7.0 mL) and chloroform (10 mL). The reaction mixture was stirred at room temperature and monitored with TLC (10% EtOAc-hexane) for the consumption of the starting material. The reaction mixture was concentrated and kept in the fridge overnight. Compound 9 was collected by filtration and rinsed with hexane to give 0.06 g (32%) of yellow needle-like crystals: mp 158e161 C; IR (cm 3.1.4. General procedure for the synthesis of the ethyl imidate hydrochloride intermediates 7a-l, 11 and 12 Acetyl chloride (16 equivalents for compounds 6a-l except 6b needed 24 equivalents and 8 equivalents for 9 and 10) was added dropwise to a suspension of 6a-l, 9 or 10 (1.0 mmol) in absolute ethanol (24 equivalents for compounds 6a-l except 6b needed 36 equivalents and 12 equivalents for 9 and 10) and dry chloroform at 0 C. The reaction was allowed to warm up to room temperature and stirring was continued for 1e3 days. 3.1.4.9. Ethyl 4-(5-(4-ethylphenyl)furan-2-yl)benzimidate 7i. The reaction mixture was cooled to 0 C and saturated solution of sodium bicarbonate was added dropwise until the gas evolution ceased. The organic layer was extracted, washed with water, dried over dry MgSO 4 and evaporated to give 0.10 g (89%) of 7i as yellow solid: mp 250e252 C; IR (cm 3.1.5. General procedure for the synthesis of furan-amidines 1, 2 and 8c-l, and pyrrole-13 and N-methylpyrrole amidine acetates 14 Ammonium acetate (4.0 mmol) was added to a suspension of furan-7a-m, pyrrole-11 and N-methylpyrrole imidate hydrochlorides 12 (1.0 mmol) in anhydrous ethanol. The mixture was stirred at room temperature for 1e3 days. 3.1.6. Synthesis of reduced N-ribosyl dihydronicotinamide NRH NADH (0.50 g, 0.69 mmol) was dissolved in 20 mL of 0.4 M sodium carbonate/bicarbonate buffer, pH 10.0, and incubated at 37 C for 16 h with 0.1 unit of phosphodiesterase 1 type IV (phosphodiesterase I from Crotalus atrox western diamondback rattlesnake) and 500 units of alkaline phosphatase type VII-S. After complete digestion of NADH, the mixture was freeze-dried. The dried powder was extracted with methanol (5 Â 6 mL), and this methanol extract was dried by rotary evaporation and dissolved in 5.0 mL of water. The NRH was then purified by preparative HPLC performed on a microsorb C18 column (21.2 Â 250 mm), eluted with 10% methanol in water over 15 m at a flow rate of 15.0 mL/m, using a 1.0 mL injection size. The NRH peak was detected at a wavelength of 350 nm. This peak from each injection was collected, freeze-dried and stored at 4 C. 
Molecular modelling
The X-ray crystal structure of human NQO2 (PDB code 1QR2, resolution 2 Å) was obtained from the Protein Bank database (PDB) [29] . The inhibitor structures were built using MOE 2011.10 software and docking was performed using GOLD 5.1 [36] . The binding affinities of the docked inhibitors were calculated using the ChemScore scoring function. The active site of NQO2 was defined as being within radius 15 Å of atom N5 of the FAD cofactor [14] . The top 10 solutions for each ligand were retained and analyzed for favorable interactions within the active site of NQO2, including low protein ligand clash, lipophilic contacts and hydrogen bonding interactions.
Inhibition of recombinant human NQO2 and NQO1 enzyme activity
The activity of NQO2 in the presence of putative inhibitors was determined spectrophotometrically by recording the rate of DCPIP reduction in the presence of NRH.The rate of the reduction was followed for 1 min at 37 C in cuvettes of 1.0 cm width containing a final volume of 1.0 mL: 940 ml phosphate buffer (50.0 mM, pH 7.4), 10 ml NQO2 (5 Â 10 À3 mg/mL), 20.0 ml NRH (10.0 mM), 20.0 ml DCPIP (2.0 mM), 10.0 ml DMSO (in the control sample), and 10.0 ml inhibitor (5 samples of different concentration). All the experiments were performed in triplicate on three separate occasions. In each independent experiment fresh solutions of NRH (10.0 mM), DCPIP (2.0 mM) and NQO2 (5 Â 10 À3 mg/mL) were prepared. NRH and NQO2 were dissolved in 50 mM phosphate buffer (50 mM, pH 7.4) and kept at 0 C. DCPIP was dissolved in deionized water. The inhibitor stock solution was prepared by dissolving the inhibitor in DMSO. 10-fold serial dilutions were completed using DMSO and buffer to give five different concentrations of the inhibitor with the final DMSO concentration being 1% v/v. IC 50 values were determined as 50% reduction in the enzyme activity compared to control. DCPIP is also a substrate for NQO1, so the DCPIP assay was also performed to test the effect of the furan-amidines 8 on NQO1 activity.
However, 200 mM NADH was used as a co-substrate instead of NRH. Furan-amidines 8 were screened at 10 mM for their inhibition of NQO1 enzyme activity, however non were shown to inhibit the enzyme.
Cell toxicity determined using the MTT assay
MDA-MB 468, MDA-MB 231, MCF-7, and T47D breast cancer cell lines were obtained from the American Type Culture Collection. Cells were seeded between 1000 and 3000 per well into 96-well plates and left overnight to allow cell attachment. Cells were then treated with different compounds at various concentrations ranging between 10 nM and 100 mM for 96 h. MTT ((3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to determine cell survival. MTT was prepared in sterile PBS at a concentration of 5.0 mg/mL and was used at a final concentration of 2.5 mg/mL. Cells were incubated with MTT for 4h. The medium was aspirated and the formazan crystals formed were dissolved in DMSO to measure absorbance. The absorbance was measured at 540 nm using the spectrophotometric multi-well plate reader. GraphPad prism5 software package was used to analyze data and generate survival curves. The measured optical density is directly proportional to cell density; therefore, the concentration of compound that decreases cell density by 50% relative to the control (vehicle only), is considered as the concentration of compound reducing cellular proliferation by 50%, which is in this case considered as the IC 50 . All toxicity experiments were repeated at least three times on separate occasions.
DNA melting
Calf thymus DNA lyophilized powder (1.0 mg, Sigma Aldrich) was dissolved in deionized water (1.0 mL) and kept at 2e8 C overnight.
10.0 ml aliquot of calf thymus DNA solution (1.0 mg/mL) was diluted with 990.0 ml buffer. The melting temperatures of calf thymus DNA in the absence and presence of ligands were determined spectrophotometrically using a Varian Cary-400 UV-Visible spectrophotometer connected to a Cary Peltier temperature controller, operating under Varian Cary WinUV software. T m profiles were collected by recording the UV absorbance of DNA at 260 nm over a temperature range of 25e98 C. Quartz cuvettes with a path-length of 1 cm and a final volume of 1.0 mL were used, which contained 980 ml phosphate buffer (7.5 mM NaH 2 PO 4 , 1 mM EDTA, pH 7.4), 10 ml calf thymus DNA (10 mg/mL), and 10.0 ml inhibitor (1.0 mM). All the experiments were performed in triplicates, three independent times, from which SE were determined. In all experiments, a heating and cooling rate of 0.1 C/min was maintained for the used temperature range with a data interval of 0.1 C. T m values corresponding to the half-transition of the thermal denaturation process of the DNA duplex were calculated as the maxima of the first-order derivatives of the melting curves using Excel.
3.6. P. falciparum (3D7) was cultured according to [37] with minor modifications
The media was RPMI 1640 supplemented with 0.2% NaHCO3, 0.2% D-Glucose, 0.5% Albumax II (Invitrogen), 100 mg Hypoxanthine and 10 mM Gentamicin; the gas mixture was 5% O 2 , 5% CO 2 in N 2 .
Growth impairment of asynchronous erythrocyte cultures of Plasmodium falciparum strain 3D7, was initiated at~0.2% parasitemia in the presence of titration curves of each compound. In triplicates of concentrations spanning from 200 mM to 200 pM using 96 well plates; preventing evaporation. Maximum DMSO concentration was 0.6%. After two full cycles ( ̴ 4days), cultures were fixed and stained with Acridine Orange (used at 0.4 mg/mL). Inhibition of growth was evaluated by flow cytometry on BD Fortessa.
